In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.
New studies highlight smoother tolerability, easier routines, and practical safety updates that make the rivastigmine patch an increasingly caregiver-friendly option.
Three major GLP-1 trials came out in late 2025. One weight-loss drug slowed early Alzheimer’s decline, while two others failed. Surprisingly, this mixed pattern may point the way toward a promising new treatment direction.
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.
Leqembi is one of the first Alzheimer’s treatments proven to slow decline. A new MRI study helps explain what it can—and cannot—do in the brain’s early months, offering clearer expectations for caregivers.
NEW RESEARCH: A diabetes medication already helping millions, called Jardiance, improves memory, strengthens blood flow, and supports overall brain health in pre- and early Alzheimer’s.
Some everyday medicines may nudge dementia risk higher — but safer, equally effective alternatives often exist. Here’s how to replace high-risk drugs with brain-friendlier options
IMAGINE THIS: Instead of going to an infusion center for treatment, you can switch to a weekly injection at home. That’s now a reality for many Alzheimer’s patients.
Getting out into the fresh air and taking a walk does good things for your brain and well-being, researchers say.
A new test that can be completed in less than three minutes enables simple, accurate detection of cognitive impairment and Alzheimer’s in cognitively normal adults, including those with no symptoms of dementia. Find out more.
Scientists say the neurons responsible for transforming experiences into memories are always the first to go in Alzheimer’s. Now they’re taking a closer look to try to figure out why, and what to do about it.
Getting out into the fresh air and taking a walk does good things for your brain and well-being, researchers say.
A new test that can be completed in less than three minutes enables simple, accurate detection of cognitive impairment and Alzheimer’s in cognitively normal adults, including those with no symptoms of dementia. Find out more.
Scientists say the neurons responsible for transforming experiences into memories are always the first to go in Alzheimer’s. Now they’re taking a closer look to try to figure out why, and what to do about it.
A research study finds when young healthy men had a full, uninterrupted night of rest, their blood levels showed a reduced level of tau, the biomarker for Alzheimer’s disease. The level was higher when they lost just one night of sleep. Learn more.
No spam, only news and updates.
